Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years

Oksana Hamidi, William F. Young, Nicole M. Iñiguez-Ariza, Nana Esi Kittah, Lucinda Gruber, Cristian Bancos, Shrikant Tamhane, Irina Bancos

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Context: Malignant pheochromocytoma (PHEO) and paraganglioma (PGL) are rare and knowledge of the natural history is limited. Objective: We aimed to describe baseline characteristics and outcomes of patients with malignant PHEO and PGL (PPGL) and to identify predictors of shorter survival. Design: Retrospective review of patients with malignant PPGL evaluated from 1960 to 2016. Setting: Referral center. Patients: The group comprised 272 patients. Main Outcome Measures: Baseline description, survival outcomes, and predictors of shorter survival were evaluated in patients with rapidly progressive (n = 29) and indolent disease (n = 188). Results: Malignant PPGL was diagnosed at a median age of 39 years (range, 7 to 83 years), with synchronous metastases in 96 (35%) patients. In 176 (65%) patients, metastases developed at a median of 5.5 years (range, 0.3 to 53.4 years) from the initial diagnosis. Median follow-up was 8.2 years (range, 0.01 to 54.1 years). Median overall and disease-specific survivals were 24.6 and 33.7 years, respectively. Shorter survival correlated with male sex (P = 0.014), older age at the time of primary tumor (P = 0.0011), synchronous metastases (P , 0.0001), larger primary tumor size (P = 0.0039), elevated dopamine (P = 0.0195), and not undergoing primary tumor resection (P ,0.0001). There was no difference in the type of primary tumor or presence of SDHB mutation. Conclusions: The clinical course of patients with malignant PPGL is remarkably variable. Rapid disease progression is associated with male sex, older age at diagnosis, synchronous metastases, larger tumor size, elevated dopamine, and not undergoing resection of primary tumor. An individualized approach to patients with metastatic PPGL is warranted.

Original languageEnglish (US)
Pages (from-to)3296-3305
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume102
Issue number9
DOIs
StatePublished - Sep 1 2017
Externally publishedYes

Fingerprint

Paraganglioma
Pheochromocytoma
Tumors
Survival
Neoplasm Metastasis
Dopamine
Neoplasms
Natural History
Disease Progression
Referral and Consultation
Outcome Assessment (Health Care)
Mutation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Hamidi, O., Young, W. F., Iñiguez-Ariza, N. M., Kittah, N. E., Gruber, L., Bancos, C., ... Bancos, I. (2017). Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. Journal of Clinical Endocrinology and Metabolism, 102(9), 3296-3305. https://doi.org/10.1210/jc.2017-00992

Malignant pheochromocytoma and paraganglioma : 272 patients over 55 years. / Hamidi, Oksana; Young, William F.; Iñiguez-Ariza, Nicole M.; Kittah, Nana Esi; Gruber, Lucinda; Bancos, Cristian; Tamhane, Shrikant; Bancos, Irina.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 102, No. 9, 01.09.2017, p. 3296-3305.

Research output: Contribution to journalArticle

Hamidi, O, Young, WF, Iñiguez-Ariza, NM, Kittah, NE, Gruber, L, Bancos, C, Tamhane, S & Bancos, I 2017, 'Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years', Journal of Clinical Endocrinology and Metabolism, vol. 102, no. 9, pp. 3296-3305. https://doi.org/10.1210/jc.2017-00992
Hamidi, Oksana ; Young, William F. ; Iñiguez-Ariza, Nicole M. ; Kittah, Nana Esi ; Gruber, Lucinda ; Bancos, Cristian ; Tamhane, Shrikant ; Bancos, Irina. / Malignant pheochromocytoma and paraganglioma : 272 patients over 55 years. In: Journal of Clinical Endocrinology and Metabolism. 2017 ; Vol. 102, No. 9. pp. 3296-3305.
@article{607c018484ec4ffd80dec31d7c366fdd,
title = "Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years",
abstract = "Context: Malignant pheochromocytoma (PHEO) and paraganglioma (PGL) are rare and knowledge of the natural history is limited. Objective: We aimed to describe baseline characteristics and outcomes of patients with malignant PHEO and PGL (PPGL) and to identify predictors of shorter survival. Design: Retrospective review of patients with malignant PPGL evaluated from 1960 to 2016. Setting: Referral center. Patients: The group comprised 272 patients. Main Outcome Measures: Baseline description, survival outcomes, and predictors of shorter survival were evaluated in patients with rapidly progressive (n = 29) and indolent disease (n = 188). Results: Malignant PPGL was diagnosed at a median age of 39 years (range, 7 to 83 years), with synchronous metastases in 96 (35{\%}) patients. In 176 (65{\%}) patients, metastases developed at a median of 5.5 years (range, 0.3 to 53.4 years) from the initial diagnosis. Median follow-up was 8.2 years (range, 0.01 to 54.1 years). Median overall and disease-specific survivals were 24.6 and 33.7 years, respectively. Shorter survival correlated with male sex (P = 0.014), older age at the time of primary tumor (P = 0.0011), synchronous metastases (P , 0.0001), larger primary tumor size (P = 0.0039), elevated dopamine (P = 0.0195), and not undergoing primary tumor resection (P ,0.0001). There was no difference in the type of primary tumor or presence of SDHB mutation. Conclusions: The clinical course of patients with malignant PPGL is remarkably variable. Rapid disease progression is associated with male sex, older age at diagnosis, synchronous metastases, larger tumor size, elevated dopamine, and not undergoing resection of primary tumor. An individualized approach to patients with metastatic PPGL is warranted.",
author = "Oksana Hamidi and Young, {William F.} and I{\~n}iguez-Ariza, {Nicole M.} and Kittah, {Nana Esi} and Lucinda Gruber and Cristian Bancos and Shrikant Tamhane and Irina Bancos",
year = "2017",
month = "9",
day = "1",
doi = "10.1210/jc.2017-00992",
language = "English (US)",
volume = "102",
pages = "3296--3305",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Malignant pheochromocytoma and paraganglioma

T2 - 272 patients over 55 years

AU - Hamidi, Oksana

AU - Young, William F.

AU - Iñiguez-Ariza, Nicole M.

AU - Kittah, Nana Esi

AU - Gruber, Lucinda

AU - Bancos, Cristian

AU - Tamhane, Shrikant

AU - Bancos, Irina

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Context: Malignant pheochromocytoma (PHEO) and paraganglioma (PGL) are rare and knowledge of the natural history is limited. Objective: We aimed to describe baseline characteristics and outcomes of patients with malignant PHEO and PGL (PPGL) and to identify predictors of shorter survival. Design: Retrospective review of patients with malignant PPGL evaluated from 1960 to 2016. Setting: Referral center. Patients: The group comprised 272 patients. Main Outcome Measures: Baseline description, survival outcomes, and predictors of shorter survival were evaluated in patients with rapidly progressive (n = 29) and indolent disease (n = 188). Results: Malignant PPGL was diagnosed at a median age of 39 years (range, 7 to 83 years), with synchronous metastases in 96 (35%) patients. In 176 (65%) patients, metastases developed at a median of 5.5 years (range, 0.3 to 53.4 years) from the initial diagnosis. Median follow-up was 8.2 years (range, 0.01 to 54.1 years). Median overall and disease-specific survivals were 24.6 and 33.7 years, respectively. Shorter survival correlated with male sex (P = 0.014), older age at the time of primary tumor (P = 0.0011), synchronous metastases (P , 0.0001), larger primary tumor size (P = 0.0039), elevated dopamine (P = 0.0195), and not undergoing primary tumor resection (P ,0.0001). There was no difference in the type of primary tumor or presence of SDHB mutation. Conclusions: The clinical course of patients with malignant PPGL is remarkably variable. Rapid disease progression is associated with male sex, older age at diagnosis, synchronous metastases, larger tumor size, elevated dopamine, and not undergoing resection of primary tumor. An individualized approach to patients with metastatic PPGL is warranted.

AB - Context: Malignant pheochromocytoma (PHEO) and paraganglioma (PGL) are rare and knowledge of the natural history is limited. Objective: We aimed to describe baseline characteristics and outcomes of patients with malignant PHEO and PGL (PPGL) and to identify predictors of shorter survival. Design: Retrospective review of patients with malignant PPGL evaluated from 1960 to 2016. Setting: Referral center. Patients: The group comprised 272 patients. Main Outcome Measures: Baseline description, survival outcomes, and predictors of shorter survival were evaluated in patients with rapidly progressive (n = 29) and indolent disease (n = 188). Results: Malignant PPGL was diagnosed at a median age of 39 years (range, 7 to 83 years), with synchronous metastases in 96 (35%) patients. In 176 (65%) patients, metastases developed at a median of 5.5 years (range, 0.3 to 53.4 years) from the initial diagnosis. Median follow-up was 8.2 years (range, 0.01 to 54.1 years). Median overall and disease-specific survivals were 24.6 and 33.7 years, respectively. Shorter survival correlated with male sex (P = 0.014), older age at the time of primary tumor (P = 0.0011), synchronous metastases (P , 0.0001), larger primary tumor size (P = 0.0039), elevated dopamine (P = 0.0195), and not undergoing primary tumor resection (P ,0.0001). There was no difference in the type of primary tumor or presence of SDHB mutation. Conclusions: The clinical course of patients with malignant PPGL is remarkably variable. Rapid disease progression is associated with male sex, older age at diagnosis, synchronous metastases, larger tumor size, elevated dopamine, and not undergoing resection of primary tumor. An individualized approach to patients with metastatic PPGL is warranted.

UR - http://www.scopus.com/inward/record.url?scp=85031049270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031049270&partnerID=8YFLogxK

U2 - 10.1210/jc.2017-00992

DO - 10.1210/jc.2017-00992

M3 - Article

C2 - 28605453

AN - SCOPUS:85031049270

VL - 102

SP - 3296

EP - 3305

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 9

ER -